Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 6, Issue 5, 2007, Pages 1517-1525

  Yin, Limei ^a   Morishige, Ken Ichirou ^b   Takahashi, Toshifumi ^a   Hashimoto, Kae ^b   Ogata, Seiji ^b   Tsutsumi, Seiji ^a   Takata, Keiko ^a   Ohta, Tsuyoshi ^a   Kawagoe, Jun ^a   Takahashi, Kazuhiro ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; RHO KINASE; TYROSINE; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; FOCAL ADHESION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRESS FIBER; UMBILICAL VEIN;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34250724961     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0689     Document Type: Article

References (34)

1. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005;9:777-94.
2. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-80.
3. Dvorak HF, Detmar M, Claffey KP, Nagy JA, van deWater L, Senger DR. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107:233-5.
4. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999;253:117-30.
5. Kiosses WB, Daniels RH, Otey C, Bokoch GM, Schwartz MA. A role for p21-activated kinase in endothelial cell migration. J Cell Biol 1999;147:831-44.
6. Ridley AJ. Stress fibres take shape. Nat Cell Biol 1999;1:64-6.
7. Le Boeuf F, Houle F, Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004;279:39175-85.
8. van Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003;23:211-7.
9. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002;80:629-38.
10. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci 2001;22:32-9.
11. Tamura M, Nakao H, Yoshizaki H, et al. Development of specific Rhokinase inhibitors and their clinical application. Biochim Biophys Acta 2005;1754:245-52.
12. Takanashi Y, Ishida T, Kirchmeier MJ, Shuaib A, Allen TM. Neuroprotection by intrathecal application of liposome-entrapped fasudil in a rat model of ischemia. Neurol Med Chir (Tokyo) 2001;41:107-14.
13. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rhokinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004;109:2234-9.
14. Wolfrum S, Dendorfer A, Rikitake Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004;24:1842-7.
15. Ying H, Biroc SL, Li WW, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006;5:2158-64.
16. Amano M, Chihara K, Nakamura N, et al. Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells 1998;3:177-88.
17. Guedez L, Rivera AM, Salloum R, et al. Quantitative assessment of angiogenic response by the directed in vivo angiogenesis assay. Am J Pathol 2003;162:1431-9.
18. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-81.
19. Horwitz AR, Parsons JT. Cell migration - movin' on. Science 1999;286:1102-3.
20. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275:10661-72.
21. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 2003;31:1171-7.
22. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
23. Kothakota S, Azuma T, Reinhard C, et al. Caspase 3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294-8.
24. Gavrieli Y, Sherman Y, Ben-Sasson A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
25. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
26. Seo D, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80.
27. Satoh S, Kobayashi T, Hitomi A, et al. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn J Pharmacol 1999;80:41-8.
28. Toshima Y, Satoh S, Ikegaki I, Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000;31:2245-50.
29. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-93.
30. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002;105:1545-7.
31. 2+ sensitization of prostaglandin F2-induced contraction of rabbit aortae. J Physiol 2003;546:823-36.
32. Hippenstiel S, Schmeck B, N'Guessan PD, et al. Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am J Physiol Lung Cell Mol Physiol 2002;283:L830-8.
33. Li X, Liu L, Tupper JC, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-16.
34. Somlyo AV, Phelps C, Dipierro C, et al. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 2003;17:223-34.